Parkman Healthcare Partners’s Amicus Therapeutics FOLD Stock Holding History

Parkman Healthcare Partners’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,487,283	Closed	-$21.2M	–	100
2025 Q4	$21.2M	Sell	1,487,283 -200,035	-12%	-$1.97M	2.02%	17
2025 Q3	$13.3M	Buy	1,687,318 +1,078,681	+177%	+$7.68M	1.39%	23
2025 Q2	$3.49M	Buy	608,637 +39,685	+7%	+$256K	0.4%	67
2025 Q1	$4.64M	Sell	568,952 -215,424	-27%	-$1.99M	0.55%	53
2024 Q4	$7.39M	Buy	784,376 +179,058	+30%	+$1.86M	0.98%	39
2024 Q3	$6.46M	Buy	605,318 +102,855	+20%	+$1.12M	0.83%	43
2024 Q2	$4.98M	Buy	502,463 +275,740	+122%	+$2.83M	0.67%	53
2024 Q1	$2.67M	Buy	+226,723	New	+$2.9M	0.33%	76

Other funds holding FOLD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Parkman Healthcare Partners's FOLD Position: Q1 2026 in Review

Parkman Healthcare Partners sold out of Amicus Therapeutics (FOLD) in Q1 2026, closing a stake of 1,487,283 shares — an estimated $21.2M sold.

Parkman Healthcare Partners first reported a position in FOLD in Q1 2024 and held it in 8 quarters. The position peaked at $21.2M in Q4 2025. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

Parkman Healthcare Partners reported no remaining Amicus Therapeutics position as of Q1 2026 after selling out during the quarter.
Parkman Healthcare Partners sold 1,487,283 Amicus Therapeutics shares in Q1 2026, an estimated $21.2M.
Parkman Healthcare Partners first reported a position in Amicus Therapeutics in Q1 2024 and held it in 8 quarters.
Parkman Healthcare Partners's Amicus Therapeutics position peaked at $21.2M in Q4 2025.
298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Parkman Healthcare Partners's 13F filing for Q1 2026, filed 15 May 2026.